Drug-induced liver injury: Development of a MILLIPLEX® MAP multiplexed assay panel for emerging biomarkers

Brought to you by:

First Name *

Last Name *

Email *

Phone Number *

Company *

Company Address *

City *

Country *

State/Province *

Postal Code *

Job Title *

Company Size

Industry *

Get the White Paper

FREE White Paper

Drug-induced Liver Injury: Development of a MILLIPLEX® MAP Multiplexed assay Panel for Emerging Biomarkers

Sponsored by EMD Millipore

Drug-induced liver injury (DILI) is an adverse event that results in withdrawal of drugs from market. As drugs may cause liver injury through various mechanisms, measuring multiple biomarkers is required to determine the potential for hepatotoxicity in early drug development. EMD Millipore’s MILLIPLEX® MAP Rat Liver Injury Panel can measure PSTC-investigated hepatotoxicity enzyme biomarkers simultaneously.

Privacy Policy

This data may be used by the sponsor to provide you with information within the scope of this white paper. Any information you submit by this form will only be used for the purposes indicated. You can trust Advantage Business Media not to rent, sell, exchange, or give your information to any third party without permission.